tiprankstipranks
JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
Japanese Market
4552
JCR Pharmaceuticals Co., Ltd.
RESEARCH TOOLSreports
Want to see JP:4552 full AI Analyst Report?

JCR Pharmaceuticals Co., Ltd. (4552) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

4552 Analyst Ratings

Hold
5Ratings
Hold
1 Buy
4 Hold
0 Sell
Based on 5 analysts giving stock ratings to
JCR
Pharmaceuticals Co., Ltd.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4552 Stock 12 Month Forecast

Average Price Target

¥564.00
▼(-20.79% Downside)
Based on 5 Wall Street analysts offering 12 month price targets for JCR Pharmaceuticals Co., Ltd. in the last 3 months. The average price target is ¥564.00 with a high forecast of ¥900.00 and a low forecast of ¥430.00. The average price target represents a -20.79% change from the last price of ¥712.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"429":"¥429","547":"¥547","665":"¥665","783":"¥783","901":"¥901"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥900.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":564,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥564.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":430,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥430.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[429,547,665,783,901],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,465,498.46153846153845,531.9230769230769,565.3846153846154,598.8461538461538,632.3076923076923,665.7692307692307,699.2307692307693,732.6923076923076,766.1538461538462,799.6153846153845,833.0769230769231,866.5384615384615,{"y":900,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,465,472.61538461538464,480.2307692307692,487.84615384615387,495.46153846153845,503.0769230769231,510.6923076923077,518.3076923076923,525.9230769230769,533.5384615384615,541.1538461538462,548.7692307692307,556.3846153846154,{"y":564,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,465,462.3076923076923,459.61538461538464,456.9230769230769,454.2307692307692,451.53846153846155,448.84615384615387,446.15384615384613,443.46153846153845,440.7692307692308,438.0769230769231,435.38461538461536,432.6923076923077,{"y":430,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":599.204,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":493.69,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":580.812,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":614.692,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":623.45,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":588.049,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":749.321,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":700.153,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":595.916,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":649.018,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":594,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":543,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":465,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target¥900.00Average Price Target¥564.00Lowest Price Target¥430.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on JP:4552
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
¥500
Hold
-29.78%
Downside
Reiterated
06/09/26
JCR Pharmaceuticals Co., Ltd. (4552) Gets a Hold from Morgan Stanley
Nomura Analyst forecast on JP:4552
Unknown Analyst
Nomura
Not Ranked
Nomura
¥430
Hold
-39.61%
Downside
Reiterated
06/05/26
JCR Pharmaceuticals Co., Ltd. (4552) Receives a Hold from Nomura
SBI Securities Analyst forecast on JP:4552
Unknown Analyst
SBI Securities
Not Ranked
SBI Securities
¥450
Hold
-36.80%
Downside
Reiterated
06/04/26
SBI Securities Remains a Hold on JCR Pharmaceuticals Co., Ltd. (4552)
Citi Analyst forecast on JP:4552
Unknown Analyst
Citi
Not Ranked
Citi
¥540
Hold
-24.16%
Downside
Reiterated
05/25/26
Citi Sticks to Its Hold Rating for JCR Pharmaceuticals Co., Ltd. (4552)
Jefferies Analyst forecast on JP:4552
Miyabi Yamakita
Jefferies
Jefferies
¥900
Buy
26.40%
Upside
Upgraded
04/16/26
JCR Pharmaceuticals Co., Ltd. (4552) was upgraded to a Buy Rating at Jefferies
UBS Analyst forecast on JP:4552
Kasumi Haruta
UBS
UBS
¥600
Hold
-15.73%
Downside
Reiterated
09/29/25
JCR Pharmaceuticals Co., Ltd. (4552) Gets a Hold from UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on JP:4552
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
¥500
Hold
-29.78%
Downside
Reiterated
06/09/26
JCR Pharmaceuticals Co., Ltd. (4552) Gets a Hold from Morgan Stanley
Nomura Analyst forecast on JP:4552
Unknown Analyst
Nomura
Not Ranked
Nomura
¥430
Hold
-39.61%
Downside
Reiterated
06/05/26
JCR Pharmaceuticals Co., Ltd. (4552) Receives a Hold from Nomura
SBI Securities Analyst forecast on JP:4552
Unknown Analyst
SBI Securities
Not Ranked
SBI Securities
¥450
Hold
-36.80%
Downside
Reiterated
06/04/26
SBI Securities Remains a Hold on JCR Pharmaceuticals Co., Ltd. (4552)
Citi Analyst forecast on JP:4552
Unknown Analyst
Citi
Not Ranked
Citi
¥540
Hold
-24.16%
Downside
Reiterated
05/25/26
Citi Sticks to Its Hold Rating for JCR Pharmaceuticals Co., Ltd. (4552)
Jefferies Analyst forecast on JP:4552
Miyabi Yamakita
Jefferies
Jefferies
¥900
Buy
26.40%
Upside
Upgraded
04/16/26
JCR Pharmaceuticals Co., Ltd. (4552) was upgraded to a Buy Rating at Jefferies
UBS Analyst forecast on JP:4552
Kasumi Haruta
UBS
UBS
¥600
Hold
-15.73%
Downside
Reiterated
09/29/25
JCR Pharmaceuticals Co., Ltd. (4552) Gets a Hold from UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering JCR Pharmaceuticals Co., Ltd.

3 Months
DeepSeek Drug Manufacturers - General JPTipRanks - DeepSeek
Success Rate
1/1 ratings generated profit
100%
Average Return
+0.40%
Copying DeepSeek Drug Manufacturers - General JP's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +0.40% per trade.
1 Year
DeepSeek Drug Manufacturers - General JPTipRanks - DeepSeek
Success Rate
1/1 ratings generated profit
100%
Average Return
+0.40%
Copying DeepSeek Drug Manufacturers - General JP's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +0.40% per trade.
2 Years
DeepSeek Drug Manufacturers - General JPTipRanks - DeepSeek
Success Rate
1/1 ratings generated profit
100%
Average Return
+0.40%
Copying DeepSeek Drug Manufacturers - General JP's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +0.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4552 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
1
1
1
Buy
0
0
0
0
0
Hold
2
2
1
1
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
2
2
2
5
In the current month, 4552 has received 1 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 4552 average Analyst price target in the past 3 months is 564.00.
Each month's total comprises the sum of three months' worth of ratings.

4552 Financial Forecast

4552 Earnings Forecast

The previous quarter’s earnings for 4552 were ¥3.57.
The previous quarter’s earnings for 4552 were ¥3.57.

4552 Sales Forecast

Next quarter’s sales forecast for 4552 is ¥10.40B with a range of ¥10.40B to ¥10.40B. The previous quarter’s sales results were ¥9.97B. 4552 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 4552 has Performed in-line its overall industry.
Next quarter’s sales forecast for 4552 is ¥10.40B with a range of ¥10.40B to ¥10.40B. The previous quarter’s sales results were ¥9.97B. 4552 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 4552 has Performed in-line its overall industry.

4552 Stock Forecast FAQ

What is JP:4552’s average 12-month price target, according to analysts?
Based on analyst ratings, JCR Pharmaceuticals Co., Ltd.’s 12-month average price target is 564.00.
    What is JP:4552’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for JP:4552, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is JCR Pharmaceuticals Co., Ltd. a Buy, Sell or Hold?
        JCR Pharmaceuticals Co., Ltd. has a consensus rating of Hold, which is based on 1 buy ratings, 4 hold ratings and 0 sell ratings.
          What is JCR Pharmaceuticals Co., Ltd.’s share price target?
          The average share price target for JCR Pharmaceuticals Co., Ltd. is 564.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is ¥900.00 ,and the lowest forecast is ¥430.00. The average share price target represents -20.79% Decrease from the current price of ¥712.
            What do analysts say about JCR Pharmaceuticals Co., Ltd.?
            JCR Pharmaceuticals Co., Ltd.’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.
              How can I buy shares of JCR Pharmaceuticals Co., Ltd.?
              To buy shares of JP:4552, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.